Structure-Based Design and Synthesis of Antiparasitic Pyrrolopyrimidines Targeting Pteridine Reductase 1
作者:Abedawn I. Khalaf、Judith K. Huggan、Colin J. Suckling、Colin L. Gibson、Kirsten Stewart、Federica Giordani、Michael P. Barrett、Pui Ee Wong、Keri L. Barrack、William N. Hunter
DOI:10.1021/jm500483b
日期:2014.8.14
The treatment of Human African trypanosomiasis remains a major unmet health need in sub-Saharan Africa. Approaches involving new molecular targets are important; pteridine reductase 1 (PTR1), an enzyme that reduces dihydrobiopterin in Trypanosoma spp., has been identified as a candidate target, and it has been shown previously that substituted pyrrolo[2,3-d]pyrimidines are inhibitors of PTR1 from Trypanosoma
非洲人类锥虫病的治疗仍然是撒哈拉以南非洲地区未满足的主要健康需求。涉及新分子目标的方法很重要;蝶啶还原酶 1 (PTR1) 是一种在锥虫属中减少二氢生物蝶呤的酶,已被确定为候选靶标,之前已表明取代的吡咯并 [2,3- d ] 嘧啶是布氏锥虫PTR1 的抑制剂( J. Med. Chem. 2010 , 53 , 221–229)。在本研究中,61 个新的吡咯并 [2,3- d]嘧啶已经制备,设计了 23 种与 PTR1 复合的化合物的新晶体结构,并在屏幕上评估了对 PTR1 的酶抑制活性和体外抗锥虫活性。八种化合物在两个筛选中都具有足够的活性,可以进行体内评估。因此,尽管获得了小鼠 I 期疾病模型中锥虫杀灭活性的证据,但这些化合物对小鼠的毒性太大,无法进一步开发。